Dietary modifications are frequently used to treat inflammatory bowel diseases (IBDs). In new research in mice, researchers from the University of Southern California have shown that one strategy, known as the fasting-mimicking diet (FMD), changes the gut microbiota in a manner that reduces IBD pathology. The results of the murine study were published March 5 in the journal Cell Reports.
The FMD involves eating only vegan, plant-based foods over a period of several days to trick the body into entering a period of fasting. In mice, the FMD has previously been shown to play a role in reducing the symptoms of several chronic illnesses, like multiple sclerosis and diabetes.
In this study, the researchers first induced IBD symptoms and pathology by feeding mice dextran sodium sulfate (DSS), a molecule that causes gut inflammation in mice. Markers of IBD pathology included gut leakiness, infiltration of the immune cells in the gut, reduced length of the gut, and blood in the stools. The mice then received multiple FMD cycles involving several days of human-grade vegan foods. Another group of DSS-treated mice underwent water-only fasting. Mice receiving the FMD showed reduced intestinal inflammation, increased stem cell number, stimulated protective gut microbiota and reversed intestinal pathology caused by DSS. In contrast, the water-only fasting increased regenerative and reduced inflammatory markers but did not reverse IBD pathology.
"In both groups of mice, we saw markers of regeneration in the gut," says lead author Valter Longo, PhD, Edna M. Jones Professor of Gerontology and Professor of Biological Sciences at USC. "But looking at the length of the colon of the small intestine and inflammation, only the FMD brings them back to better health while the water-only fasting does not."
Many of the ingredients in the diet are known to foster growth of certain bacterial populations as pre-biotics. "Because of its content, this diet is facilitating changes in the microbiota, including repopulation or major changes in the population of Lactobacillus," says Longo.
In this study, the researchers found that transplants of Lactobacillus or fecal microbiota from DSS- and FMD-treated mice, reversed DSS-induced colon shortening, reduced inflammation, and increased colonic stem cells.
"Together with the FMD, we think that Lactobacillus reseeding is really responsible for many of these effects," says Longo. He concludes that the contents of the FMD, along with the fasting protocol, allowed the mice gut microbiota to repopulate bacterial populations like Lactobacillus that are responsible for achieving part of the improved IBD pathology effects.
The mice received the same FMD diet as the team has given to human study subjects in other trials. "You wouldn't think mice would have that much Lactobacillus, but they were given a human diet so it seems to promote growth of bacteria normally associated with a healthy human vegan diet," Longo explains.
In this paper, the researchers re-examined patient samples from an earlier FMD human clinical trial unrelated to IBD. They studied white blood cells and inflammatory markers like C-reactive protein (CRP). "We found that, in the people who had higher inflammatory markers like CRP, the white blood cells were elevated as you would expect in a system that is in a pre-inflammatory disease condition," says Longo. "Then we showed that the inflammatory markers and white blood cells came down in response to multiple cycles of the FMD."
Looking ahead the researchers are finalizing the protocol for a randomized clinical trial of a modified FMD in humans to see if the microbiota changes and produces any effects on IBD pathology.
###
This study was funded in part by the National Institutes of Health, the National Institute on Aging, and the Glenn Foundation for Medical Research.
Cell Reports, Rangan and Choi et al. "Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology" https://www.cell.com/cell-reports/fulltext/S2211-1247(19)30181-0
Cell Reports (@CellReports), published by Cell Press, is a weekly open-access journal that publishes high-quality papers across the entire life sciences spectrum. The journal features reports, articles, and resources that provide new biological insights, are thought-provoking, and/or are examples of cutting-edge research. Visit: http://www.cell.com/cell-reports. To receive Cell Press media alerts, contact press@cell.com.
Journal
Cell Reports